A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ION-682884, an Antisense Inhibitor of Transthyretin Production, in Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis
Phase of Trial: Phase I/II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs AKCEA-TTR-LRx (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
- 12 Dec 2018 Status changed from not yet recruiting to recruiting.
- 03 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.
- 13 Nov 2018 New trial record